Dementia

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Abstract  Background Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug ‐ cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine ‐ are widely licensed for dementia due to Alzheimer’s disease, and rivastigmine is also licensed for Parkinson’s disease dementia. […]

Share

Remotely delivered information, training and support for informal caregivers of people with dementia

Abstract Background Many people with dementia are cared for at home by unpaid informal caregivers, usually family members. Caregivers may experience a range of physical, emotional, financial and social harms, which are often described collectively as caregiver burden. The degree of burden experienced is associated with characteristics of the caregiver, such as gender, and characteristics […]

Share

Souvenaid for Alzheimer’s disease

Abstract Background Souvenaid is a dietary supplement with a patented composition (Fortasyn Connect™)which is intended to be used by people with Alzheimer’s disease (AD). It has been designed to support the formation and function of synapses in the brain, which are thought to be strongly correlated with cognitive function. If effective, it might improve symptoms […]

Share

Pharmacotherapies for sleep disturbances in dementia

Abstract Background Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant carer distress, increased healthcare costs, and institutionalisation. Although non‐drug interventions are recommended as the first‐line approach to managing these problems, drug treatment is often sought and used. However, […]

Share

Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings

Abstract Background People with dementia living in the community, that is in their own homes, are often not engaged in meaningful activities. Activities tailored to their individual interests and preferences might be one approach to improve quality of life and reduce challenging behaviour. Objectives To assess the effects of personally tailored activities on psychosocial outcomes […]

Share

Aromatherapy for dementia

Abstract Background Medications licensed for the treatment of dementia have limited efficacy against cognitive impairment or against the distressed behaviours (behavioural and psychological symptoms, or behaviour that challenges) which are also often the most distressing aspect of the disorder for caregivers. Complementary therapies, including aromatherapy, are attractive to patients, practitioners and families, because they are […]

Share

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia

Abstract Background Dementia is a worldwide concern. Its global prevalence is increasing. At present, there is no medication licensed to prevent or delay the onset of dementia. Inflammation has been suggested as a key factor in dementia pathogenesis. Therefore, medications with anti‐inflammatory properties could be beneficial for dementia prevention. Objectives To evaluate the effectiveness and […]

Share

Simulated presence therapy for dementia

Abstract Background Dementia is a common and serious neuropsychiatric syndrome, characterised by progressive cognitive and functional decline. The majority of people with dementia develop behavioural disturbances, also known as behavioural and psychological symptoms of dementia (BPSD). Several non‐pharmacological interventions have been evaluated to treat BPSD in people with dementia. Simulated presence therapy (SPT), an intervention […]

Share

Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment

Abstract Background Mild cognitive impairment (MCI) due to Alzheimer’s disease is the symptomatic predementia phase of Alzheimer’s disease dementia, characterised by cognitive and functional impairment not severe enough to fulfil the criteria for dementia. In clinical samples, people with amnestic MCI are at high risk of developing Alzheimer’s disease dementia, with annual rates of progression […]

Share

Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late lifemaintaining cognitive function in cognitively healthy people in late life

Abstract Background Increasing age is associated with a natural decline in cognitive function and is the greatest risk factor for dementia. Cognitive decline and dementia are significant threats to independence and quality of life in older adults. Therefore, identifying interventions that help to maintain cognitive function in older adults or that reduce the risk of […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share